Abstract: The histological and immunohistological changes in the adrenal medulla could explain the failure of outcome of adrenal autograft therapy in Parkinson's disease.
Introduction
In the 1980s and 90s, the medical community held significant hope for "adrenal medullary autografts" as a treatment for Parkinson’s disease (PD). The concept was straightforward: transplant dopamine-producing chromaffin cells from a patient’s own adrenal gland into the striatum to replace lost neurons. As autologous tissue, these grafts were expected to avoid immune rejection. However, clinical outcomes were consistently disappointing, with poor graft survival and minimal symptomatic improvement.
This study investigates the hypothesis that PD is a systemic disorder affecting the peripheral nervous system simultaneously with the central nervous system. By examining the adrenal medulla in the AS/AGU rat model, researchers sought to determine if the "donor" tissue used in these historical trials was already pathologically compromised.
Methods
The researchers utilized the AS/AGU rat, a unique spontaneous mutant model that exhibits dopamine depletion and motor impairments mirroring human PD. The study compared four cohorts (n=6 per group): 1-week-old healthy Albino Swiss (AS) rats, adult healthy AS rats, 1-week-old AS/AGU rats, and adult AS/AGU rats.
The evaluation employed several histological and immunohistochemical techniques:
- H&E Staining: To assess general tissue morphology and identify signs of inflammation or necrosis.
- Periodic Acid Schiff (PAS) Staining: To detect "Lewy-body-like" inclusion bodies.
- Immunohistochemistry (IHC): Targeting S100 (sustentacular support cells), Ubiquitin (protein-degradation system), and Tyrosine Hydroxylase (TH) (the rate-limiting enzyme for dopamine synthesis).
- Digital Image Analysis: High-resolution scans were quantified using Aperio ImageScope software to provide objective area-percentage measurements.
Results
Histological and Structural Degeneration
General histological examination revealed significant damage in the adrenal medulla of the PD model rats. While healthy controls showed normal architecture, the AS/AGU rats exhibited vascular congestion and inflammatory infiltration. In adult AS/AGU rats, areas of necrosis and pyknotic nuclei were evident, indicating active cell death.
Furthermore, the expression of S100 protein was markedly reduced in AS/AGU rats. Since S100-positive sustentacular cells provide vital support to chromaffin cells, their loss likely renders the dopamine-producing cells highly vulnerable to degeneration.
Protein Aggregation and Systemic Failure
The study found that the same pathological markers seen in the PD brain are present in the adrenal medulla. AS/AGU rats showed a significantly higher percentage of chromaffin cells containing PAS-positive inclusion bodies compared to healthy controls. This was accompanied by a significant decrease in ubiquitin expression, suggesting a failure of the ubiquitin-proteasome system (UPS) to clear misfolded proteins, leading to toxic aggregation.
Loss of Dopaminergic Function
The most critical finding regarding the failure of autograft therapy was the state of Tyrosine Hydroxylase (TH) expression. In adult AS/AGU rats, TH levels plummeted compared to healthy adults. In many instances, the immunoreaction was almost entirely negative, signifying that the cells had lost their ability to synthesize dopamine long before they would have been harvested for transplantation.
Discussion
The results provide a compelling explanation for the failure of adrenal medullary autografts. The pathological process of PD is not confined to the brain; it severely compromises the adrenal medulla as well. The "spare parts" intended for transplantation—the chromaffin cells—are themselves riddled with inflammation, protein-clearing failures, and a loss of the very enzymes needed to produce dopamine.
The presence of Lewy-body-like inclusions and the breakdown of the UPS in the adrenal medulla suggest that the peripheral nervous system undergoes a parallel degenerative process. Consequently, transplanting this diseased tissue into the brain is unlikely to provide therapeutic benefit, as the cells are already in a state of advanced dysfunction.
Conclusion
This study reinforces the view of Parkinson’s disease as a systemic condition. The failure of adrenal autograft therapy was not merely a surgical or immunological issue but a biological one: the donor tissue was already diseased. Understanding these peripheral changes is essential for developing future therapies and highlights the need for systemic rather than purely localized treatment strategies.
Summary updated